• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Three-year safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized Alpharadin in symptomatic prostate cancer trial.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    PIIS030228381730516X.pdf
    Size:
    415.8Kb
    Format:
    PDF
    Description:
    Open access full text article ...
    Download
    Authors
    Parker, C
    Coleman, R
    Sartor, O
    Vogelzang, N
    Bottomley, D
    Heinrich, D
    Helle, S
    O'Sullivan, J
    Fosså, S
    Chodacki, A
    Wiechno, P
    Logue, John P
    Seke, M
    Widmark, A
    Johannessen, D
    Hoskin, P
    James, N
    Solberg, A
    Syndikus, I
    Kliment, J
    Wedel, S
    Boehmer, S
    Dall'Oglio, M
    Franzén, L
    Bruland, O
    Petrenciuc, O
    Staudacher, K
    Li, R
    Nilsson, S
    Show allShow less
    Affiliation
    The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK
    Issue Date
    2017-07-10
    
    Metadata
    Show full item record
    Abstract
    In Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial, radium-223 versus placebo prolonged overall survival with favorable safety in castration-resistant prostate cancer patients with symptomatic bone metastases. Long-term radium-223 monitoring underlies a comprehensive safety and risk/benefit assessment.
    Citation
    Three-year safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized Alpharadin in symptomatic prostate cancer trial. 2017 Eur Urol
    Journal
    European Urology
    URI
    http://hdl.handle.net/10541/620492
    DOI
    10.1016/j.eururo.2017.06.021
    PubMed ID
    28705540
    Type
    Article
    Language
    en
    ISSN
    1873-7560
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.eururo.2017.06.021
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
    • Authors: Hoskin P, Sartor O, O'Sullivan JM, Johannessen DC, Helle SI, Logue J, Bottomley D, Nilsson S, Vogelzang NJ, Fang F, Wahba M, Aksnes AK, Parker C
    • Issue date: 2014 Nov
    • Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.
    • Authors: Parker C, Finkelstein SE, Michalski JM, O'Sullivan JM, Bruland Ø, Vogelzang NJ, Coleman RE, Nilsson S, Sartor O, Li R, Seger MA, Bottomley D
    • Issue date: 2016 Nov
    • Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
    • Authors: Uemura H, Uemura H, Nagamori S, Wakumoto Y, Kimura G, Kikukawa H, Yokomizo A, Mizokami A, Kosaka T, Masumori N, Kawasaki Y, Yonese J, Nasu Y, Fukasawa S, Sugiyama T, Kinuya S, Hosono M, Yamaguchi I, Akagawa T, Matsubara N
    • Issue date: 2019 May
    • Alpha-emitter radium-223 in the management of solid tumors: current status and future directions.
    • Authors: Nilsson S
    • Issue date: 2014
    • Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.
    • Authors: Sartor O, Hoskin P, Coleman RE, Nilsson S, Vogelzang NJ, Petrenciuc O, Staudacher K, Thuresson M, Parker C
    • Issue date: 2016 Jul
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.